Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer
| Autor: | Scott J. Antonia, F.S. Hodi, Maurice Pérol, Matthew D. Hellmann, Adam J. Schoenfeld, D.S.W. Tan, Scott N. Gettinger, Martin Reck, Melissa Lynne Johnson, Justin F. Gainor, Natasha B. Leighl, Mark M. Awad, Benjamin Solomon, Enriqueta Felip, Tony Mok, Solange Peters, Christine M. Lovly, J-C. Soria |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Programmed Cell Death 1 Receptor B7-H1 Antigen Internal medicine Carcinoma Non-Small-Cell Lung medicine Humans Prospective Studies Lung cancer Lung business.industry Cancer Hematology Immunotherapy medicine.disease Blockade Clinical trial Clinical research medicine.anatomical_structure business Progressive disease |
| Zdroj: | Annals of oncology : official journal of the European Society for Medical Oncology. 32(12) |
| ISSN: | 1569-8041 |
| Popis: | Acquired resistance (AR) to programmed cell death protein 1/programmed death-ligand 1 [PD-(L)1] blockade is frequent in non-small-cell lung cancer (NSCLC), occurring in a majority of initial responders. Patients with AR may have unique properties of persistent antitumor immunity that could be re-harnessed by investigational immunotherapies. The absence of a consistent clinical definition of AR to PD-(L)1 blockade and lack of uniform criteria for ensuing enrollment in clinical trials remains a major barrier to progress; such clinical definitions have advanced biologic and therapeutic discovery. We examine the considerations and potential controversies in developing a patient-level definition of AR in NSCLC treated with PD-(L)1 blockade. Taking into account the specifics of NSCLC biology and corresponding treatment strategies, we propose a practical, clinical definition of AR to PD-(L)1 blockade for use in clinical reports and prospective clinical trials. Patients should meet the following criteria: received treatment that includes PD-(L)1 blockade; experienced objective response on PD-(L)1 blockade (inclusion of a subset of stable disease will require future investigation); have progressive disease occurring within 6 months of last anti-PD-(L)1 antibody treatment or rechallenge with anti-PD-(L)1 antibody in patients not exposed to anti-PD-(L)1 in 6 months. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|